Microcap Ledger OnKure Therapeutics, Inc. $OKUR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Boulder, CO
- Fiscal year end
- December 31
- Shares outstanding
- 40,496,309 [10-Q 2026-08-04]
What the company doesAI summary of filing
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule precision medicines that selectively target mutated forms of phosphoinositide 3-kinase alpha (PI3Kα) while sparing the wild-type enzyme. The company's lead product candidate, OKI-219, is a highly selective inhibitor of PI3Kα H1047R mutation currently in Phase 1 clinical trials (PIKture-01) for advanced breast cancer in multiple patient populations. OnKure is pre-revenue and has never generated product sales; the company has incurred significant net losses since inception and faces substantial doubt regarding its ability to continue as a going concern. Beyond OKI-219, the company is pursuing additional discovery programs targeting other common PI3Kα mutations and vascular malformations, with plans to announce a pan-mutant development candidate in the first quarter of 2026. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$30.50M | −$23.29M | $166.50M | [10-Q 2026-08-04] |
| FY ended Dec 2025 | — | −$59.52M | −$51.83M | $59.05M | [10-K 2026-03-12] |
| FY ended Dec 2024 | $0.00 | −$52.67M | −$51.12M | $110.76M | [10-K 2025-03-10] |
- Quarterly cash burn
- −$11.65M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2023-11-09 | 33,311,787 | [10-Q 2023-11-13] |
| 2024-03-26 | 33,420,808 | [10-K 2024-03-28] |
| 2024-04-24 | 33,420,808 | [10-K/A 2024-04-26] |
| 2024-05-03 | 33,420,808 | [10-Q 2024-05-07] |
| 2024-08-08 | 33,428,808 | [10-Q 2024-08-13] |
| 2026-03-11 | 13,673,565 | [10-K 2026-03-12] |
| 2026-05-04 | 40,395,480 | [10-Q 2026-05-05] |
| 2026-08-03 | 40,496,309 | [10-Q 2026-08-04] |
- Shelf registration
- S-3 filed 2026-04-24; declared effective 2026-05-04 [S-3 2026-04-24]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-21 | Saccomano Nicholas A | sell | 87 | $2.97 | [4 2026-09-23] |
| 2026-09-21 | Leverone Jason A. | sell | 302 | $2.97 | [4 2026-09-23] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 8-K | Director or officer change |
| 2026-08-10 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-04 | 8-K | Results of operations |
| 2026-08-04 | 10-Q | Quarterly report |
| 2026-06-04 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $OKUR
Email me when OnKure Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.